ClinicalTrials.gg
CompletedNCT00650455Updated Jul 21, 2008

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

A Phase 4 interventional study of valdecoxib and naproxen in Arthritis, Rheumatoid, sponsored by Pfizer. Completed at 55 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-07-21.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
489
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 152 studies in Arthritis, Rheumatoid by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.

Enrollment
17th of 86
489 · median 155
Started
2003
with 6 others
Phase 4
17 of 152
none open now
Registered
45th of 152
by date

Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 17th largest by enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2003, is one of 17 in phase 4, and was the 45th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 152 studies in Arthritis, Rheumatoid by Pfizer is open now. Recruiting first, the newest first:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Arthritis, Rheumatoid by Pfizer, or all of them as a file.
02

Study summary

The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • valdecoxib, severe rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of severe rheumatoid arthritis (RA) for at least 6 months
  • The Rheumatoid Arthritis must have been treated with a stable regimen including a non-steroidal anti-inflammatory drug (NSAID), as well as methotrexate for at least 12 weeks -OR- an NSAID (for at least 12 weeks plus a tumor necrosis factor inhibitor (i.e., adalimumab [Humira®] for a minimum of 5 doses on a regular schedule, etanercept [Enbrel®] for 6 weeks, infliximab (Remicade®) for 3 doses and currently on a stable regimen of infusions not more than every 8 weeks)

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of any other inflammatory arthritis or a secondary, noninflammatory type of arthritis (eg, osteoarthritis (OA) or fibromyalgia) that, in the investigator's opinion, was symptomatic enough to interfere with the evaluation of the effect of valdecoxib on the patient's primary diagnosis of Rheumatoid Arthritis were excluded from the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
489 participants (actual)

Study arms

  • Active comparator
    Arm 2

    Drug: naproxen

  • Placebo comparator
    Arm 3

    Drug: placebo

  • Active comparator
    Arm 1

    Drug: valdecoxib

Interventions

  • valdecoxib 10 mg tablet once daily for 12 weeks

  • naproxen 500 mg capsule twice daily for 12 weeks

  • Drugplacebo

    placebo tablet every morning and capsule every evening for 12 weeks

06

What researchers measure

Primary outcomes

  1. ACR-20 criteria responder

    Time frame: Week 12

Secondary outcomes

  1. Patient's Global Assessment of Disease Activity

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  2. Duration of morning stiffness

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  3. Incidence and time to withdrawal due to insufficient clinical response

    Time frame: Study endpoint

  4. Physician's Global Assessment of Disease Activity

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  5. swollen joint count

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  6. Adverse events

    Time frame: Baseline, Week 1, Week 6, and Week 12

  7. Average rescue medication usage per day

    Time frame: Study endpoint

  8. Short Form-36 Acute Health Survey

    Time frame: Baseline, Week 1, Week 6, and Week 12

  9. tender joint count

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  10. One-Week Severity of Dyspepsia Assessment

    Time frame: Baseline, Week 1, and Week 12

  11. C-reactive protein

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  12. laboratory tests

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  13. vital signs

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  14. physical examinations

    Time frame: Screening and Week 12

  15. ACR-N

    Time frame: Study endpoint

  16. Patient Treatment Satisfaction Scale

    Time frame: Week 1 and Week 6

  17. Patient's assessment of arthritis pain (VAS)

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

  18. Health Assessment Questionnaire (HAQ) Disability Index

    Time frame: Screening, Baseline, Week 1, Week 6, and Week 12

07

Study locations

55 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35249-7201, United States
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Glendale, Arizona 85304, United States
  • Pfizer Investigational Site
    Glendale, Arizona 85308, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85202, United States
  • Pfizer Investigational Site
    Paradise Valley, Arizona 85253, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85012, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona 95260, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85719, United States
  • Pfizer Investigational Site
    Fullerton, California 92835, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    San Diego, California 92120, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida 33334, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32204, United States
  • Pfizer Investigational Site
    Jupiter, Florida 33458, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Orlando, Florida 32804, United States
  • Pfizer Investigational Site
    Palm Harbor, Florida 34684, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33401, United States
  • Pfizer Investigational Site
    Zephyrhills, Florida 33540, United States
  • Pfizer Investigational Site
    Idaho Falls, Idaho 83404, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62704, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46227, United States
  • Pfizer Investigational Site
    Frederick, Maryland 21702, United States
  • Pfizer Investigational Site
    Greenbelt, Maryland 20770, United States
  • Pfizer Investigational Site
    Lansing, Michigan 48910, United States
  • Pfizer Investigational Site
    Jackson, Mississippi 39216, United States
  • Pfizer Investigational Site
    Marlton, New Jersey 8053, United States
  • Pfizer Investigational Site
    Passaic, New Jersey 07055, United States
  • Pfizer Investigational Site
    Teaneck, New Jersey 07666, United States
  • Pfizer Investigational Site
    Brooklyn, New York 11203, United States
  • Pfizer Investigational Site
    New York, New York 10021, United States
  • Pfizer Investigational Site
    New York, New York 10035, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43214, United States
  • Pfizer Investigational Site
    Allentown, Pennsylvania 18103, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Erie, Pennsylvania 16508, United States
  • Pfizer Investigational Site
    Johnstown, Pennsylvania 15904, United States
  • Pfizer Investigational Site
    Mechanicsburg, Pennsylvania 17055, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • Pfizer Investigational Site
    Philadephia, Pennsylvania 19152, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02906, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    El Paso, Texas 79902, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76107, United States
  • Pfizer Investigational Site
    Plano, Texas 75093, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78232, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78240, United States
  • Pfizer Investigational Site
    Arlington, Virginia 22204, United States
  • Pfizer Investigational Site
    Seattle, Washington 98166-2967, United States
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1M1, Canada
  • Pfizer Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 0H6, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2008
First posted
Apr 1, 2008
Start
Feb 2003
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Last update
Jul 21, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00650455
Lead sponsor
Pfizer
First posted
Apr 1, 2008
Start date
Feb 2003
Primary completion
Jan 2005
Completion
Jan 2005
Last update
Jul 21, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valdecoxib · Naproxen

Start the discussion